VDyne Appoints Mike Buck as Chairman and CEO to Lead Next Phase of its TTVR Program

Buck brings over 30 years of leadership experience in cardiovascular medical technology to guide VDyne's clinical advancement.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

VDyne Inc., a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system, has appointed Mike Buck as its new Chairman and Chief Executive Officer. Buck has over 30 years of leadership experience in the cardiovascular medical technology industry, previously serving as CEO of Verge Medical and founder/CEO of TRUVIC Medical.

Why it matters

VDyne's TTVR system has received FDA Breakthrough Device designation and the company is advancing toward CE Mark approval and initiating its U.S. pivotal clinical study. Buck's appointment is expected to help guide VDyne through this critical next phase as it works to bring its innovative TTVR therapy to market.

The details

VDyne has conducted clinical studies across 15 countries, with more than 100 successful TTVR procedures to date. The company is developing its TTVR system to treat tricuspid regurgitation, a condition where the tricuspid valve in the heart does not close properly, allowing blood to flow backwards. Buck's prior experience includes serving as President of Cardinal Health's Medical Products Division and holding senior leadership roles at Abbott, including leading its global Vascular business and Licensing and Acquisitions function.

  • VDyne has received FDA Breakthrough Device designation.
  • VDyne is advancing toward CE Mark approval.
  • VDyne is preparing to initiate its U.S. pivotal clinical study.

The players

VDyne Inc.

A privately held medical device company based in Maple Grove, Minnesota, developing a transcatheter tricuspid valve replacement (TTVR) system for the treatment of tricuspid regurgitation.

Mike Buck

The new Chairman and Chief Executive Officer of VDyne Inc. He brings over 30 years of leadership experience in the cardiovascular medical technology industry, previously serving as CEO of Verge Medical and founder/CEO of TRUVIC Medical.

Dr. Greg Pearl

A VDyne Board Member who stated that Buck's leadership will be critical in guiding the company through its next phase as it advances its clinical programs.

Got photos? Submit your photos here. ›

What they’re saying

“VDyne has built a strong clinical foundation, and the opportunity to improve the lives of patients with tricuspid regurgitation is significant. I look forward to working alongside this team as we advance the technology and continue building the clinical evidence behind it.”

— Mike Buck, Chairman and Chief Executive Officer, VDyne Inc.

“Mike brings deep experience in structural heart and a proven ability to build and lead strong teams. As VDyne advances its clinical programs, his leadership will be critical in guiding the company through its next phase.”

— Dr. Greg Pearl, VDyne Board Member

What’s next

VDyne is preparing to initiate its U.S. pivotal clinical study for its TTVR system, which will be a key milestone as the company works towards regulatory approval and commercialization.

The takeaway

VDyne's appointment of industry veteran Mike Buck as Chairman and CEO signals the company's commitment to advancing its innovative TTVR therapy to treat tricuspid regurgitation, a condition with significant unmet medical need. Buck's deep experience in cardiovascular medical technology is expected to be invaluable as VDyne enters this critical next phase of clinical development and regulatory approval.